Lilly Makes Billions of Weight-Loss Pills
Digest more
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares ...
Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...
Eli Lilly announced that its experimental weight-loss pill, orforglipron, meets most of the criteria for the U.S. Food and ...
Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year ...
Eli Lilly and Co. LLY has surged into the top decile of quality rankings among S&P 500 peers, achieving a percentile score of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback